All News

Novartis was ranked 4th in Fortune magazine’s Change the World list and cited for developing an innovative new cancer treatment, working to expand access to healthcare and supporting value-based pricing.

Sandoz invites young entrepreneurs to enter the "Sandoz HACk", a new global competition to help solve healthcare access challenges.

Carlos Sattler, MD, is vice president of clinical development and medical affairs at Sandoz. The op-ed below was first published on Morning Consult.

European generic and biosimilar industry is successfully fulfilling its mission to be the main supplier of high-quality medicines to patients in Europe, both increasing patient access and partnering for sustainable healthcare.

The Medicine Maker’s Biosimilars special edition, including an interview with Carol Lynch, Sandoz Head of Biopharmaceuticals & Oncology Injectables.

The publication presents an analysis of the US market after the FDA officially approved the first US biosimilar – Zarxio (filgrastim-sndz) from Sandoz.

A peer-reviewed article authored by Mark McCamish, John Pakulski, and Gillian Woollett on the interchangeability of biologics.